A statement released earlier today by Brean Capital about IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) bumps the target price to $8.00
- Updated: October 3, 2016
In a report released on Monday October 03, 2016 Brean Capital increased the stock price target of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to $8.00 reporting a possible upside of 2.76%.
Just yesterday IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) traded 2.38% higher at $2.13. IntelliPharmaCeutics Intl Inc (USA)’s 50-day moving average is $1.89 and its 200-day moving average is $1.83. The last stock price is up 17.49% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 63,498 shares of IPCI traded hands, down from an average trading volume of 180,900
Recent Performance Chart
IntelliPharmaCeutics Intl Inc (USA) has 52 week low of $1.41 and a 52 week high of $3.19 and has a market capitalization of $0.
Brief Synopsis On IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company's Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It has developed several drug delivery systems and a pipeline of products and product candidates in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS). Its products include Focalin XR, Keppra XR, Effexor XR, Protonix, Seroquel XR, Lamictal XR, Pristiq, Oleptro, Coreg CR, OxyContin and Lyrica.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.